AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$TBPH

Theravance Biopharma, Inc.

Price · $TBPHvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TBPH in the last 7 days.

Insider · 30dAll trades →
Buys
—
0 txs
Sells
$227K
28 txs
Winningham Rick E5× · —
10b5-1 share of filings11%
See all $TBPH insider activity →
Top stories · $TBPHMore →
SEP 28·gurufocus.comHigh

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

TBPH sentiment & insider activity

Recent TBPH coverage spans insider activity and mergers & acquisitions.

In the last 30 days, TBPH insiders filed 28 SEC Form 4 transactions — no purchases and 28 sales ($227K). The most active reporter was Winningham Rick E, CHIEF EXECUTIVE OFFICER, with 5 filings. 11% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving TBPH

  • Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

    gurufocus.com · Sep 28, 2026

  • The insider sale may signal lack of confidence, putting slight downward pressure on the stock.

    SEC EDGAR · Sep 25, 2026

  • The insider sale removes a large block of shares, likely signaling limited confidence and could pressure the stock lower.

    SEC EDGAR · Sep 25, 2026

  • The insider sale removes a significant insider stake, potentially signaling lack of confidence but the amount is modest relative to market cap.

    SEC EDGAR · Sep 25, 2026

  • The insider sale is small and likely has minimal impact on the stock price.

    SEC EDGAR · Sep 25, 2026

AlphAI scores every news story that mentions TBPH with an AI model for sentiment and relevance, and aggregates insider trades from Theravance Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TBPH

Score
SEP 28$ZYMEHighgurufocus.com

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

3 min read

Related tickers

More in Biotechnology